Overview
- Roemmers bought 100% of Laboratorios Craveri, taking its brands, production sites, and about 310 employees, with an internal memo saying staff will remain while the final structure is still to be defined.
- Sector outlets led by Pharmabiz reported a price near US$60 million, which the companies have not publicly confirmed.
- Craveri’s board cited flat drug sales in units since 2009, growing dominance by larger players, and higher regulatory costs as reasons to sell.
- The seller had been losing ground and money, dropping from 29th in 2017 to 36th in pharmacy sales rankings and carrying roughly ARS 9.33 billion in liabilities with rejected checks this year.
- The deal adds to Roemmers’ recent buying streak that included Sidus in 2025, IMVI through Gramon in 2024, and a 30% stake in Tuteur, while Craveri brings plants in Caballito and Villa del Parque plus a project in Pilar.